A single nucleotide polymorphism (SNP) is the most frequent type of variation in the genome. There are around 10 million SNPs that have been identified in the human genome [1] . Because SNPs are highly conserved throughout evolution and within a population, the map of SNPs serves as an excellent genotypic marker for research. The elucidation of SNP information will contribute to an individual's susceptibility to disease and responsiveness to drug toxicity and medical intervention [2, 3] . Nowadays, a variety of techniques have been used to perform SNP genotyping, but these techniques required whole blood as the sample. Dried blood spot (DBS) specimens require less material and are substantially more stable (several months at room temperature) than whole blood [4] . Thus, the simplicity of sample preparation, long time storage and convenient transport make DBS to be a cost-effective and suitable alternative tool for collecting blood sample.
Plavix (clopidogrel) and warfarin are wildly used antithrombotic drugs in the treatment and prevention of thrombotic diseases, including myocardial infarction, ischemic stroke, and venous thrombosis [5] . However, because of genetic variation, the two drugs have wide inter-individual variation in dose resulting in the risk of serious bleeding complications [6, 7] . Many studies have shown that genetic status can greatly influence an individual patient's warfarin or Plavix dosing [8] [9] [10] [11] [12] [13] [14] [15] .
So the Food and Drug Administration changed the warfarin label to encourage lower initial doses in patients who have the VKORC1-1639G.A, CYP2C9*2, or CYP2C9*3 allele in August 2007 [16] and added pharmacogenetic information to the Plavix product label because of genetic differences in CYP2C19 in March 2010. In this study, we developed a method to detect genotyping of DBS specimens about Plavix and warfarin using SurPlexTM-xTAG method.
All oligonucleotides were synthesized by Invitrogen Corporation (Carlsbad, USA). PCR primers used for the genotyping assay (Table 1) were unmodified. Allele-specific primer extension (ASPE) primers consist of two sequences: a tag sequence (according to Luminex tag sequence) and the allele-specific sequence ( Table 1) . Universal anti-tags (probes) were amino (NH2)-modified for coupling to carboxylated microspheres. Tag sequences used for validation of the universal array were labeled with biotin. To evaluate the specificity of this method, the plasmids (pGEM-T-Easy; Promega, Madison, USA) containing wild-type (WT) alleles of CYP2C9, CYP2C19, VKORC1, and ABCB1 were constructed. The mutant-type plasmids were derived from WT plasmids using the TaKaRa Mutant Best kit (TaKaRa, Dalian, China).
Approximately 30 ml of whole blood was spotted on 3-mm filter paper (Whatman, Wisconsin, USA). After drying, a 6-mm disk was cut out from the sampling paper. Additionally, the 6-mm disk was placed into a 1.5-ml Eppendorf cup (Hamburg, Germany), with 100 ml sterile water, and then placed in a boiling water bath for 15 min to make the cells lyse. After gentle vortexes, the mixture was centrifuged at 10,000 g for 5 min, then 10 ml supernatants were pipetted and used as DNA source for amplification.
Multiplex PCR about warfarin was performed in a 50 ml volume containing: 1 Â Ex Taq polymerase buffer, 2.5 mM MgCl 2 , 0.2 mM dNTPs, 0.2 mM each of the primers, 1.0 U Ex Taq HS DNA polymerase (TaKaRa) and 10 ml supernatant of boiling DBS as template DNA. Thermo cycling was performed using 30 cycles of 958C for 30 s, 568C for 30 s, and 728C for 30 s. The reaction was concluded with a final extension step of 728C for 10 min and the product was kept at 48C until use. A similar approach was used to enrich DNA fragments of Plavix-related genes using 3 mM MgCl 2 . Exonuclease I and shrimp alkaline phosphatase (EXO-SAP) reaction was performed in a 25-ml volume containing: 1 Â SAP buffer, 1 U shrimp alkaline phosphatase (inactivating any remaining nucleotides) (TaKaRa), 10 U exonuclease I (degrading any remaining PCR primers) (New England Biolabs, Ipswich, USA) and 7.5 ml PCR product. Samples were then incubated at 378C for 30 min, followed by 20 min incubation at 808C to inactivate the enzymes. Multiplex ASPE was carried out using 5 ml of treated PCR product in a final volume of 20 ml. Each reaction consisted of 1 Â SAP buffer, 1.25 mM MgCl 2 , 5 mM biotin-dCTP, 5 mM each of dATP, dTTP, dGTP; 0.75 U of Platinum Tsp; and 25 nM ASPE primer pool. The ASPE primer sequences are listed in Table 1 . The ASPE reactions were incubated at 968C for 2 min and then subject to 40 cycles at 948C for 30 s, 528C for 1 min, and 748C for 2 min. According to Luminex's one-step carbodiimide coupling procedure [17] , probes were coupled to carboxylated microspheres. Each coated bead population was suspended and stored in TE buffer. ASPE products were mixed with the probe-bearing beads at 968C for 2 min, followed by 15-min incubation at 568C. Streptavidin-conjugated phycoerythrin (25 ml; 10 mg/l; Jackson ImmunoResearch Laboratories, West Grove, USA) was added into the mixture and incubated for 5 min at 568C. The reactions were carried out on the Luminex 200 system at 568C. The median fluorescence intensity (MFI) was computed for each set of beads in the sample.
In order to determine the specificity, the six type-specific probes and the universal probes were individually coupled to defined bead sets and hybridized to ASPE products derived from 2 Â 10 6 copies of cloned plasmid template. Results showed that all of the genotypes of Plavix-related genes was highly specific (Fig. 1) , and warfarin was also highly specific (Fig. 1) . All of the signals were between 1200 and 5900 MFI. The cross-reaction rates of Plavix and warfarin were lower than 3% and 5.5%, respectively.
In order to determine whether this strategy can be applied as a diagnostic tool, we used this method in SNP genotyping. In our experiment, we first detected 20 genomic DNA samples which were extracted from peripheral blood (1 ml in an EDTA BD vacuum tube) of healthy laboratory volunteers using Whole-blood DNA purification kit (Promega) according to the manufacturer's instructions using 300 ml of elution buffer, and then selected dry blood samples which were prepared by same peripheral blood to detect. Results showed that the data were absolutely uniform. CYP2C19 genotyping showed that 11 samples were *1/*1, 1 samples was *2/*2, 6 samples were heterozygous *1/*2, and 2 samples were heterozygous *1/*3. ABCB1 (C3435T) genotyping showed that four samples were homozygous CC, 15 were heterozygous CT, and 1 was homozygous for the TT genotype. CYP2C9 genotyping showed that all of 20 samples were *1/*1. VKORC1 (G-1639A) genotyping showed that 2 samples were homozygous GG, 3 were heterozygous GA, and 15 were homozygous for the AA genotype.
To further validate the results, we randomly chose different genotyping samples which were detected by SurPlexTMxTAG method to be sequenced by Invitrogen Corporation. The results were consistent with those of SurPlexTM-xTAG method. SurPlexTM-xTAG method is a rising technique for routine SNP genotyping. Compared with Sanger sequencing method, it is a high-throughput, sensitive, and convenient technology. Usually, the source DNA was extracted from whole blood or all kinds of tissues using DNA purification kit, which wasted detecting time and cost. As a cost-effective and suitable alternative tool for collecting blood sample, DBS is a perfect sample from which DNA is easily released by boiling water method, and the detection data of DBS are reliable. Figure 1 . Cross-reactivity of warfarin and Plavix (A) Warfarin specificity of MEL assay for CYP2C9 and VKORC1 of all six alleles that were hybridized to the mixture of pre-coated microspheres in one reaction. The cross-reaction rate was ,5.5%. (B) Plavix specificity of MEL assay for CYP2C19 and ABCB1 of all six alleles that were hybridized to the mixture of pre-coated microspheres in one reaction. The cross-reaction rate was ,3%.
A multiplexer liquidchip platform for detecting the polymorphism In conclusion, we described a method to detect SNPs of multiple genes directly from DBS specimens on filter paper without DNA purification, which make the SNP detection to be completed within 8 h. This technology will be used in SurExam Test Center to provide pharmacogenomic diagnostic services for patients with cardiovascular events using DBS samples.
